Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA.
Stanford Prevention Research Center, Department of Medicine, and Department of Health Research and Policy, Stanford University School of Medicine, and MetaResearch Innovation Center at Stanford (METRICS), Stanford, California.
Neurosurgery. 2018 May 1;82(5):604-612. doi: 10.1093/neuros/nyx319.
The evidence base for many neurosurgical procedures has been limited. We performed a comprehensive and systematic analysis of study design, quality of reporting, and trial results of neurosurgical randomized controlled trials (RCTs).
To systematically assess the design and quality characteristics of neurosurgical RCTs.
From January 1961 to June 2016, RCTs with >5 patients assessing any 1 neurosurgical procedure against another procedure, nonsurgical treatment, or no treatment were retrieved from MEDLINE, Scopus, and Cochrane Library.
The median sample size in the 401 eligible RCTs was 73 patients with a mean patient age of 49.6. Only 111 trials (27.1%) described allocation concealment, 140 (34.6%) provided power calculations, and 117 (28.9%) were adequately powered. Significant efficacy or trend for efficacy was claimed in 226 reports (56.4%), no difference between the procedures was found in 166 trials (41.4%), and significant harm was reported in 9 trials (2.2%). Trials with a larger sample size were more likely to report randomization mode, specify allocation concealment, and power calculations (all P < .001). Government funding was associated with better specification of power calculations (P = .008) and of allocation concealment (P = .026), while industry funding was associated with reporting significant efficacy (P = .02). Reporting of funding, specification of randomization mode and primary outcomes, and mention of power calculations improved significantly (all, P < .05) over time.
Several aspects of the design and reporting of RCTs on neurosurgical procedures have improved over time. Better powered and accurately reported trials are needed in neurosurgery to deliver evidence-based care and achieve optimal outcomes.
许多神经外科手术的证据基础有限。我们对神经外科随机对照试验(RCT)的研究设计、报告质量和试验结果进行了全面系统的分析。
系统评估神经外科 RCT 的设计和质量特征。
从 1961 年 1 月至 2016 年 6 月,从 MEDLINE、Scopus 和 Cochrane Library 中检索了超过 5 例患者评估任何 1 种神经外科手术与另一种手术、非手术治疗或不治疗的 RCT。
401 项合格 RCT 的中位数样本量为 73 例患者,平均患者年龄为 49.6 岁。只有 111 项试验(27.1%)描述了分配隐匿,140 项(34.6%)提供了功效计算,117 项(28.9%)具有足够的功效。226 项报告(56.4%)声称有显著疗效或疗效趋势,166 项试验(41.4%)发现手术之间无差异,9 项试验(2.2%)报告有显著危害。样本量较大的试验更有可能报告随机模式、指定分配隐匿和功效计算(均 P <.001)。政府资助与更好地规定功效计算(P =.008)和分配隐匿(P =.026)有关,而工业资助与报告显著疗效(P =.02)有关。随着时间的推移,报告资助情况、指定随机模式和主要结局以及提及功效计算的情况显著改善(均 P <.05)。
神经外科手术 RCT 的设计和报告的几个方面随着时间的推移而有所改善。神经外科需要更好的、有足够功效的和准确报告的试验,以提供循证护理并实现最佳结果。